Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Window of Opportunity Study with Giredestrant or Tamoxifen in Premenopausal ER+/HER2− Early Breast Cancer
2023-503565-36-00Phase 2Completed
- Sponsor
- MEDSIR
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial in breast cancer comparing Giredestrant preoperative monotherapy with Tamoxifen preoperative monotherapy (2 arms). Primary endpoint: Change in Ki67 expression between baseline and post-treatment. Started May 2023; status: completed.
02
Drugs
giredestranttamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2023-503565-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503565-36-00.